Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. is a US-based biopharmaceutical company focused on developing innovative gene therapies targeting rare genetic disorders, particularly in the cardiovascular domain. Founded in 2015 in Cranbury, US, Rocket Pharmaceuticals, Inc. specializes in gene therapy solutions for rare diseases.

The company underwent a significant change in 2018 when it merged with Inotek Pharmaceuticals Corporation. Gaurav Shah serves as both the CEO and founder, with a history of involvement in biotech ventures. The company has raised a total of USD 299. 00 mn through multiple funding rounds, with the most recent being a Private Placement/Follow on in April 2019.

Rocket Pharmaceuticals, Inc. focuses on developing gene therapies for rare genetic disorders, specifically cardiovascular diseases. Their lead product, RP-A501, is in a Phase 2 pivotal clinical trial for treating Danon Disease. The company also targets conditions such as Fanconi Anemia and various cardiomyopathies, utilizing innovative gene therapy platforms across US and European markets.

In the most recent year, Rocket Pharmaceuticals reported zero revenue. The company's EBITDA for 2024 stands at USD -263. 83 mn, indicating ongoing investment in clinical development and partnerships with healthcare institutions. Rocket Pharmaceuticals aims to expand its product offerings and extend its market reach.

The company is actively working on the development of new gene therapies, with plans to launch additional products in the coming years. They are also focused on geographic expansion into new markets, particularly within Europe. The recent funding of USD 299. 00 mn will be pivotal in supporting these initiatives, enhancing their clinical trial capabilities and facilitating partnerships within the healthcare sector.

With a commitment to advancing their pipeline, Rocket Pharmaceuticals is strategically positioned for future growth.